SI-BONE Inc (SIBN) Stock Forecast & Price Target

SI-BONE Inc. is poised for significant growth, driven by a projected 12.5% increase in operating expenses, coupled with anticipated positive EBITDA by 2026. The company's US revenue growth accelerated to approximately 42% on a two-year revenue stack, bolstered by an increase in procedures per physician and a robust cash position of $110 million as of 3Q25, which enhances its capacity for investment in growth initiatives. Additionally, the expansion of its iFuse technology and the increasing contribution of outpatient surgery centers to SI joint fusion sales underscore the company's potential for continued market share gains in an underpenetrated sector.

SI-BONE Inc. faces a negative outlook due to anticipated challenges in revenue growth, particularly in the U.S. market, where low-teens revenue growth is projected, alongside continued weakness in international markets. The company's valuation metrics, such as an EV/sales/growth ratio of 0.19x, highlight a significant underperformance compared to its small- and mid-cap growth peer group's median of 0.34x, indicating market concerns about its growth prospects. Additionally, risks such as competitive pressures, patent expirations, and a potential deceleration in procedure growth exacerbate the uncertainty surrounding SI-BONE's financial performance.